Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals
© 2022. The Author(s)..
In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern. Modified vaccinia Ankara-Bavarian Nordic (MVA-BN, also known as Imvamune, JYNNEOS or Imvanex) is a third-generation smallpox vaccine that is authorized and in use as a vaccine against MPX. To date, there are no data showing MPX virus (MPXV)-neutralizing antibodies in vaccinated individuals nor vaccine efficacy against MPX. Here we show that MPXV-neutralizing antibodies can be detected after MPXV infection and after historic smallpox vaccination. However, a two-shot MVA-BN immunization series in non-primed individuals yields relatively low levels of MPXV-neutralizing antibodies. Dose-sparing of an MVA-based influenza vaccine leads to lower MPXV-neutralizing antibody levels, whereas a third vaccination with the same MVA-based vaccine significantly boosts the antibody response. As the role of MPXV-neutralizing antibodies as a correlate of protection against disease and transmissibility is currently unclear, we conclude that cohort studies following vaccinated individuals are necessary to assess vaccine efficacy in at-risk populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Nature medicine - 29(2023), 1 vom: 15. Jan., Seite 270-278 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zaeck, Luca M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 26.01.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-022-02090-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347720978 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347720978 | ||
| 003 | DE-627 | ||
| 005 | 20231227130949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-022-02090-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM347720978 | ||
| 035 | |a (NLM)36257333 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zaeck, Luca M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern. Modified vaccinia Ankara-Bavarian Nordic (MVA-BN, also known as Imvamune, JYNNEOS or Imvanex) is a third-generation smallpox vaccine that is authorized and in use as a vaccine against MPX. To date, there are no data showing MPX virus (MPXV)-neutralizing antibodies in vaccinated individuals nor vaccine efficacy against MPX. Here we show that MPXV-neutralizing antibodies can be detected after MPXV infection and after historic smallpox vaccination. However, a two-shot MVA-BN immunization series in non-primed individuals yields relatively low levels of MPXV-neutralizing antibodies. Dose-sparing of an MVA-based influenza vaccine leads to lower MPXV-neutralizing antibody levels, whereas a third vaccination with the same MVA-based vaccine significantly boosts the antibody response. As the role of MPXV-neutralizing antibodies as a correlate of protection against disease and transmissibility is currently unclear, we conclude that cohort studies following vaccinated individuals are necessary to assess vaccine efficacy in at-risk populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic |2 NLM | |
| 650 | 7 | |a TU8J357395 |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 700 | 1 | |a Lamers, Mart M |e verfasserin |4 aut | |
| 700 | 1 | |a Verstrepen, Babs E |e verfasserin |4 aut | |
| 700 | 1 | |a Bestebroer, Theo M |e verfasserin |4 aut | |
| 700 | 1 | |a van Royen, Martin E |e verfasserin |4 aut | |
| 700 | 1 | |a Götz, Hannelore |e verfasserin |4 aut | |
| 700 | 1 | |a Shamier, Marc C |e verfasserin |4 aut | |
| 700 | 1 | |a van Leeuwen, Leanne P M |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitz, Katharina S |e verfasserin |4 aut | |
| 700 | 1 | |a Alblas, Kimberley |e verfasserin |4 aut | |
| 700 | 1 | |a van Efferen, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Bogers, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Scherbeijn, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Rimmelzwaan, Guus F |e verfasserin |4 aut | |
| 700 | 1 | |a van Gorp, Eric C M |e verfasserin |4 aut | |
| 700 | 1 | |a Koopmans, Marion P G |e verfasserin |4 aut | |
| 700 | 1 | |a Haagmans, Bart L |e verfasserin |4 aut | |
| 700 | 1 | |a GeurtsvanKessel, Corine H |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Rory D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 29(2023), 1 vom: 15. Jan., Seite 270-278 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:1 |g day:15 |g month:01 |g pages:270-278 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-022-02090-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 1 |b 15 |c 01 |h 270-278 | ||